http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박치영,강지은,박상곤,김상현,김형선,정춘해 朝鮮大學校 附設 醫學硏究所 2007 The Medical Journal of Chosun University Vol.32 No.2
Background: Autoimmune hemolytic anemia (AIHA) is a very uncommon disorder with the incidence between one and three cases per a hundred thousans a year. There have been very few studies about AIHA in Korea because of its low incidence. Most AIHA studies in Korea were about case history. The aim of this study was to review the clinical features, therapy and outcome of AIHA patients in single institution clinic. Methods: We reviewed retrospectively the medical records of AIHA patients from December 2002 to December 2006. Results: Twelve patient with AIHA were identified, and their median age was 49 years (range 27-75). Male to female ratio is 9:3. The median hemoglobin level was 5.0 g/㎗ (range 2.5-8.2). Warm type AIHA was most common (8/12), cold type was three, and mixed type was one. There was histories of associated disease in six patients. Two patients were complicated by systemic lupus erythematosus and mycoplasma infection and one patient by idiopathic myelofibrosis and solid tumor. Oral steroid was used as the first-line treatment in nine patients. An initial response was observed in eight patients with complete response. One patient had not responded to the initial steroid treatment, and then showed complete response with rituximab. Two relapsed patients were treated with rituximab and partial splenic embolization. Conclusion: The majority of patients can be treated with steroid. Rituximab can improve the response rate in relapsed and refractory AIHA.